Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023.

Blepharitis, a chronic condition that causes inflammation of the eyelids, affects millions of people across the United States ...

EP: 10. Outlook on the Future of Demodex Blepharitis Treatment EP: 11. Understanding Demodex Blepharitis Pathogenesis EP: 12. Cost-Effective Medication Access in Demodex Blepharitis Treatment EP: 13.

Eric D. Donnenfeld, MD; underscores the significance of an FDA approved treatment for Demodex blepharitis as well as past alternative treatments. EP: 1. EP: 2. EP: 3.

Xdemvy ™ (lotilaner ophthalmic solution) is now available for the treatment of Demodex blepharitis. Xdemvy contains lotilaner, a gamma-aminobutyric acid-gated chloride channel inhibitor ...

The FDA approved Xdemvy, a 0.25% lotilaner ophthalmic solution, for the treatment of Demodex blepharitis, according to a press release from Tarsus Pharmaceuticals.

News for Tarsus Pharmaceuticals Tarsus Pharmaceuticals, Inc. Initiates Saturn-2, Second Pivotal Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis ...

About XDEMVY™ XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop for the treatment of Demodex blepharitis and is designed to target and ...

(RTTNews) - Tarsus Pharmaceuticals, Inc. (TARS) announced the FDA approved XDEMVY 0.25% for the treatment of Demodex blepharitis. XDEMVY is the first and only FDA approved treatment to directly ...

Readers may recall previous campaigns like Look at the Lids or Don’t Freak Out, Get Checked Out. With those in mind, earlier this week, the company announced a multi-channel consumer marketing push in ...

Demodex blepharitis is so common that it makes up more than twothirds of all blepharitis cases.In fact, nearly 58% of patients who visit an eye doctor have pathognomonic Demodex collarettes — a ...

At WCC, Tarsus will also present new long-term safety data from the extension study for the Saturn-1 pivotal Phase 2b/3 trial evaluating TP-03 for the treatment of Demodex blepharitis.